Richard Creagan, MD | |
946539 Mamalahoa Hwy, Naalehu, HI 96772-0189 | |
(808) 929-7606 | |
Not Available |
Full Name | Richard Creagan |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 946539 Mamalahoa Hwy, Naalehu, Hawaii |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063670933 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | MD5969 (Hawaii) | Primary |
Mailing Address | Practice Location Address |
---|---|
Richard Creagan, MD Po Box 189, Naalehu, HI 96772-0189 Ph: (808) 929-7606 | Richard Creagan, MD 946539 Mamalahoa Hwy, Naalehu, HI 96772-0189 Ph: (808) 929-7606 |
News Archive
Researchers at UC San Diego Health System's Department of Reproductive Medicine and the National Latino Research Center (NLRC) at Cal State San Marcos University recently presented data at the American Public Health Association Conference in Washington D.C., demonstrating the impact of text4baby, a free mobile service that provides pregnant women and new mothers in San Diego with maternal, fetal and newborn health information via text messages and connects them to national health resources.
An international team of researchers from the Universities of Leicester and Naples has examined the role of a receptor in the body that could help to prevent or reduce the effects of asthma attacks.
The first anniversary is approaching of the March, 2011, earthquake and tsunami that devastated Fukushima, Japan, and later this year debris from that event should begin to wash up on U.S. shores - and one question many have asked is whether that will pose a radiation risk.
A government study has found that more than half a million teens have had an eating disorder, most commonly in the form of binge eating disorder and bulimia, and that most of the time these go untreated.
iCo Therapeutics, a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 Diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common complications of diabetes, diabetic macular edema.
› Verified 5 days ago